一分钟看懂
这是一项关于结直肠癌的不适用研究，登记的药物或干预包括Transarterial infusion chemotherapy (TAIC)；Intravenous Chemotherapy（IVC），当前状态为招募中。登记地点显示中国西城区有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Transarterial infusion chemotherapy (TAIC)；Intravenous Chemotherapy（IVC） · 不适用
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences · 西城区
公开的入选条件
- Study population:
- Patients who meet all inclusion criteria and none of the exclusion criteria are eligible for enrolment and study treatment.
- Inclusion criteria:
- 1. Age ≥ 18 years old;
- 2. Histopathologically confirmed CRC adenocarcinoma;
- 3. Locally advanced CRC confirmed as clinical T4 stage on CT/MRI imaging, with or without synchronous liver metastases;
- 4. For patients with CRLM, hepatic tumor burden shall be lower than the burden of the primary colorectal lesion. Consequently, the multidisciplinary team (MDT) agree by consensus that CRC should be a priority target for treatment.
- 5. No prior administration of chemotherapy, targeted therapy or radiotherapy for the current malignancy;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07333053；登记信息更新于 2026-09-11。